

Mouse Anti-p57/Kip2 [LP10]: MC0565, MC0565RTU7

Intended Use: For Research Use Only

Description: p57Kip2 is a potent, tight-binding inhibitor of several G1 cyclin/Cdk complexes, and its binding is cyclin dependent. Its over-expression leads to arrest of the cell in G1 phase. Human p57Kip2 appears to have conserved the amino- and carboxy-terminal domains but has replaced the internal regions with sequences containing proline-alanine repeats. Expression patterns suggest a complex role for p57Kip2 cell cycle control and development. Because complete hydatidiform moles lack a maternal genome, p57Kip2 immunostaining is correspondingly absent, whereas hydropic abortuses and partial moles show positive staining. p57Kip2 is a marker distinguishing complete hydatidiform moles (negative) from partial moles (positive).

Specifications


Clone:	LP10
Source:	Mouse
Isotype:	IgG2b/k
Reactivity:	Human, mouse
Localization:	Nucleus
Formulation:	Antibody in PBS pH7.4, containing BSA and $\leq 0.09\%$ sodium azide (NaN ₃)
Storage:	Store at 2°- 8°C
Applications:	IHC, Flow Cyt., IF
Package:	

Description	Catalog No.	Size
p57/Kip2 Concentrated	MC0565	1 ml
p57/Kip2 Prediluted	MC0565RTU7	7 ml

IHC Procedure*

Positive Control Tissue:	Colon cancer, placenta
Concentrated Dilution:	50-200
Pretreatment:	Tris EDTA pH9.0, 15 minutes using Pressure Cooker, or 30-60 minutes using water bath at 95°-99°C
Incubation Time and Temp:	30-60 minutes @ RT
Detection:	Refer to the detection system manual

* Result should be confirmed by an established diagnostic procedure.



FFPE human colon carcinoma stained with anti-p57 using DAB

References:

1. Deregulated Expression of Mammalian lncRNA through Loss of SPT6 Induces R-Loop Formation, Replication Stress, and Cellular Senescence. Nojima T, et al. Mol Cell 72:970-984.e7, 2018.
2. Crk proteins transduce FGF signaling to promote lens fiber cell elongation. Collins TN, et al. Elife 7:N/A, 2018.
3. Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Mazur PK, et al. Nat Med 21:1163-71, 2015.